[1. LOWELL A. GOLDSMITH, STEPHEN I. KATZ, BARBARA A. GILCHREST, et al. Fitzpatrick’s Dermatology in General Medicine, 8th Ed., McGrawHill, 2012.]Search in Google Scholar
[2. BOLOGNIA JEAN L, JOSEPH L. JORIZZO, SCHAFFER JULIE V. Dermatology. Elsevier, 3 Ed, 2012.]Search in Google Scholar
[3. BRAUN-FALCO O., PLEWIG G, WOLFF HH, M. LANDTHALER. Braun-Falco's Dermatology. Third edition. Springer. 2009.]Search in Google Scholar
[4. MAHIL SK, CAPON F, BARKER JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. In: Seminars in immunopathology (Vol. 38, No. 1, pp. 11-27). Springer, Berlin, Heidelberg, 2016.10.1007/s00281-015-0539-8470657926573299]Search in Google Scholar
[5. TAMPA M, NICOLAE IL, ENE CD, et al. Vitamin C and Thiobarbituric Acid Reactive Substances (TBARS) in Psoriasis Vulgaris Related to Psoriasis Area Severity Index (PASI). REVISTA DE CHIMIE. 2017; 68(1):43-7.10.37358/RC.17.1.5385]Search in Google Scholar
[6. ŁAKUTA P, MARCINKIEWICZ K, BERGLER-CZOP B, et al. How does stigma affect people with psoriasis? Advances in Dermatology and Allergology/Postẹpy Dermatologii i Alergologii. 2017; 34(1):36.10.5114/pdia.2016.62286532910128261029]Search in Google Scholar
[7. OWCZAREK K, JAWORSKI M. Quality of life and severity of skin changes in the dynamics of psoriasis. Advances in Dermatology and Allergology/Postẹpy Dermatologii i Alergologii. 2016; 33(2):102.10.5114/pdia.2015.54873488477327279818]Search in Google Scholar
[8. MANTOVANI L, MEDAGLIA M, PIACENTINI P, et al. Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatology and therapy. 2016; 6(2):151-67.10.1007/s13555-016-0114-9490610827083437]Search in Google Scholar
[9. GHORBANIBIRGANI A, FALLAHI-KHOSHKNAB M, ZAREA K, et al. The Lived Experience of Psoriasis Patients from Social Stigma and Rejection: A Qualitative Study. Iranian Red Crescent Medical Journal. 2016; 18(7).10.5812/ircmj.27893502676627656290]Open DOISearch in Google Scholar
[10. BAKER BS. From arsenic to biologicals: a 200 year history of psoriasis. Garner Press; 2008.]Search in Google Scholar
[11. PATHIRANA D, ORMEROD AD, SAIAG P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology. 2009; 23(s2):1-70.]Search in Google Scholar
[12. TONY BURNS, STEPHEN BREATHNACH, NEIL COX, et al. Rook's textbook of dermatology. Eighth Edition, Wiley Blackwell, 2010.10.1002/9781444317633]Search in Google Scholar
[13. ZAIDI A, MENG Q, POPKIN D. Can we repurpose FDA-approved alefacept to diminish the HIV reservoir? Immunotherapy (Los Angeles, Calif.). 2015; 1(1).10.4172/2471-9552.1000104]Search in Google Scholar
[14. DUNN LK, FELDMAN SR. Alefacept treatment for chronic plaque psoriasis. Skin Therapy Lett. 2010; 15(4):1-3.]Search in Google Scholar
[15. KAFFENBERGER BH, KAFFENBERGER TM, WONG HK. Immunotargeting in the management of psoriasis. Immuno Targets and Therapy. 2013; 2:51.10.2147/ITT.S32038492835827471688]Search in Google Scholar
[16. ELLIS CN, KRUEGER GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New England Journal of Medicine. 2001; 345(4):248-55.10.1056/NEJM20010726345040311474662]Search in Google Scholar
[17. SIVAMANI RK, CORREA G, ONO Y, et al. Biological therapy of psoriasis. Indian journal of dermatology. 2010; 55(2):161.10.4103/0019-5154.62754288752220606887]Search in Google Scholar
[18. LEBWOHL M, CHRISTOPHERS E, LANGLEY R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Archives of dermatology. 2003; 139(6):719-27.10.1001/archderm.139.6.71912810502]Search in Google Scholar
[19. WCISŁO-DZIADECKA D, ZBICIAK M, BRZEZIŃSKA-WCISŁO L, et al. Anti-cytokine therapy for psoriasis-not only TNF-α blockers. Overview of reports on the effectiveness of therapy with IL-12/IL-23 and T and B lymphocyte inhibitors. Advances in Hygiene & Experimental Medicine/Postepy Higieny i Medycyny Doswiadczalnej. 2016; 70.]Search in Google Scholar
[20. GORDON KB, PAPP KA, HAMILTON TK, et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama. 2003; 290(23):3073-80.10.1001/jama.290.23.307314679270]Search in Google Scholar
[21. WHARTON JR KA, QUIGLEY C, THEMELES M, et al. JC polyomavirus abundance and distribution in progressive multifocal leukoencephalopathy (PML) brain tissue implicates myelin sheath in intracerebral dissemination of infection. PloS one. 2016; 11(5):e0155897.10.1371/journal.pone.0155897487143727191595]Search in Google Scholar
[22. SCHWAB N, ULZHEIMER JC, FOX RJ, et al. Fatal PML associated with efalizumab therapy. Insights into integrin αLβ2 in JC virus control. Neurology. 2012; 78(7):458-67.10.1212/WNL.0b013e3182478d4b328005222302546]Open DOISearch in Google Scholar
[23. TAVAZZI E, FERRANTE P, KHALILI K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clinical Microbiology and Infection. 2011; 17(12):1776-80.10.1111/j.1469-0691.2011.03653.x465950322082208]Search in Google Scholar
[24. TAN JK, APHALE A, MALAVIYA R, et al. Mechanisms of action of etanercept in psoriasis. In: Journal of Investigative Dermatology Symposium Proceedings 2007 (Vol. 12, No. 1, pp. 38-45). Elsevier.10.1038/sj.jidsymp.565003717502868]Search in Google Scholar
[25. LEONARDI CL, POWERS JL, MATHESON RT, et al. Etanercept as monotherapy in patients with psoriasis. New England Journal of Medicine. 2003; 349(21):2014-22.10.1056/NEJMoa03040914627786]Search in Google Scholar
[26. FERNÁNDEZ-TORRES RM, PARADELA S, FONSECA E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. Journal of Dermatological Treatment. 2014; 25(1):54-6.10.3109/09546634.2012.75525423210771]Search in Google Scholar
[27. Summary of product characteristics Enbrel. [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf]Search in Google Scholar
[28. PALLER AS, SIEGFRIED EC, LANGLEY RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. New England Journal of Medicine. 2008; 358(3):241-51.10.1056/NEJMoa06688618199863]Search in Google Scholar
[29. CARAZO JL, SANTOS LM, MARTINEZ VO. Safety of Etanercept in Psoriasis. Drug safety. 2006; 29(8):675-85.10.2165/00002018-200629080-00004]Search in Google Scholar
[30. GORDON KB, LANGLEY RG, LEONARDI C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. Journal of the American Academy of Dermatology. 2006; 55(4):598-606.10.1016/j.jaad.2006.05.027]Open DOISearch in Google Scholar
[31. MENTER A, TYRING SK, GORDON K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. Journal of the American Academy of Dermatology. 2008; 58(1):106-15.10.1016/j.jaad.2007.09.010]Search in Google Scholar
[32. SAURAT JH, STINGL G, DUBERTRET L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). British Journal of Dermatology. 2008; 158(3):558-66.10.1111/j.1365-2133.2007.08315.x]Search in Google Scholar
[33. PAPP K, THAÇI D, MARCOUX D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. The Lancet. 2017.10.1016/S0140-6736(17)31189-3]Open DOISearch in Google Scholar
[34. CARRASCOSA CARRILLLO JM, TORO MONTECINOS M, BALLESCÁ LÓPEZ F, et al. Correlation between trough serum levels of Adalimumab and absolute PASI score in a series of patients with psoriasis. Journal of Dermatological Treatment. 2017 Jun 12(just-accepted):1-20.]Search in Google Scholar
[35. TRACZEWSKI P, RUDNICKA L. Adalimumab in dermatology. British journal of clinical pharmacology. 2008; 66(5):618-25.10.1111/j.1365-2125.2008.03263.x]Search in Google Scholar
[36. GALL JS, KALB RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008; 2(1):115-24.]Search in Google Scholar
[37. REICH K, NESTLE FO, PAPP K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. The Lancet. 2005; 366(9494):1367-74.10.1016/S0140-6736(05)67566-6]Search in Google Scholar
[38. MENTER A, FELDMAN SR, WEINSTEIN GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 2007; 56(1):31-e1.10.1016/j.jaad.2006.07.01717097378]Search in Google Scholar
[39. FELDMAN SR, GORDON KB, BALA M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. British Journal of Dermatology. 2005; 152(5):954-60.10.1111/j.1365-2133.2005.06510.x15888152]Search in Google Scholar
[40. TAKAHASHI H, TSUJI H, ISHIDA-YAMAMOTO A, et al. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. The Journal of dermatology. 2013; 40(1):39-42.10.1111/j.1346-8138.2012.01679.x23039179]Search in Google Scholar
[41. LEONARDI CL, KIMBALL AB, PAPP KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-74.10.1016/S0140-6736(08)60725-4]Search in Google Scholar
[42. PAPP KA, LANGLEY RG, LEBWOHL M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84.10.1016/S0140-6736(08)60726-6]Search in Google Scholar
[43. PAPP KA, GRIFFITHS CE, GORDON K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. British Journal of Dermatology. 2013; 168(4):844-54.10.1111/bjd.1221423301632]Search in Google Scholar
[44. LANGLEY RG, LEBWOHL M, KRUEGER GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. British Journal of Dermatology. 2015; 172(5):1371-83.10.1111/bjd.1346925307931]Search in Google Scholar
[45. GRIFFITHS CE, STROBER BE, VAN DE KERKHOF P, et al. Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis. New England Journal of Medicine. 2010; 362(2):118-28.10.1056/NEJMoa081065220071701]Search in Google Scholar
[46. Summary of product characteristics Stelara [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf]Search in Google Scholar
[47. KOFOED K, SKOV L, ZACHARIAE C. New drugs and treatment targets in psoriasis. Acta dermato-venereologica. 2015; 95(2):133-9.10.2340/00015555-193125111317]Search in Google Scholar
[48. GODSE K. Secukinumab-First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis. Indian journal of dermatology. 2017; 62(2):195.10.4103/ijd.IJD_233_16536314528400641]Search in Google Scholar
[49. Prescribing information Cosentyx [Accessed 22.06.2017]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf]Search in Google Scholar
[50. PAPP KA, LANGLEY RG, SIGURGEIRSSON B, et al. Efficacy and safety of secukinumab in the treatment of moderate-tosevere plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. British Journal of Dermatology. 2013; 168(2):412-21.10.1111/bjd.1211023106107]Search in Google Scholar
[51. LANGLEY RG, ELEWSKI BE, LEBWOHL M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. New England Journal of Medicine. 2014; 371(4):326-38.10.1056/NEJMoa131425825007392]Search in Google Scholar
[52. FALA L. Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis. American Health & Drug Benefits. 2016; 9(Spec Feature):60.]Search in Google Scholar
[53. Summary of product characteristics Talz. [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf]Search in Google Scholar
[54. GORDON KB, BLAUVELT A, PAPP KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New England Journal of Medicine. 2016; 375(4):345-56.10.1056/NEJMoa151271127299809]Search in Google Scholar
[55. GRIFFITHS CE, REICH K, LEBWOHL M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015; 386(9993):541-51.10.1016/S0140-6736(15)60125-8]Search in Google Scholar
[56. HANLEY TL, YIU ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Therapeutics and clinical risk management. 2017; 13:315.10.2147/TCRM.S111107]Search in Google Scholar
[57. GOTTLIEB AB, LACOUR JP, KORMAN N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. Journal of the European Academy of Dermatology and Venereology. 2017; 31(4):679-85.10.1111/jdv.13990]Open DOISearch in Google Scholar
[58. GUDJONSSON JE, JOHNSTON A, ELLIS CN. Novel systemic drugs under investigation for the treatment of psoriasis. Journal of the American Academy of Dermatology. 2012; 67(1):139-47.10.1016/j.jaad.2011.06.037]Search in Google Scholar
[59. DAMSKY W, KING BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology. 2017.10.1016/j.jaad.2016.12.005]Search in Google Scholar
[60. SHREBERK-HASSIDIM R, RAMOT Y, ZLOTOGORSKI A. Janus kinase inhibitors in dermatology: A systematic review. Journal of the American Academy of Dermatology. 2017.10.1016/j.jaad.2016.12.004]Open DOISearch in Google Scholar
[61. PAPP KA, MENTER MA, ABE M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology. 2015; 173(4):949-61.10.1111/bjd.14018]Search in Google Scholar
[62. BACHELEZ H, VAN DE KERKHOF PC, STROHAL R, KUBANOV A, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. The Lancet. 2015; 386(9993):552-61.10.1016/S0140-6736(14)62113-9]Search in Google Scholar
[63. PORTS WC, KHAN S, LAN S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. British Journal of Dermatology. 2013; 169(1):137-45.10.1111/bjd.12266376119023387374]Search in Google Scholar
[64. Summary of product characteristics Otezla [Accessed 22.06.2017]. Available at: https://ec.europa.eu/health/documents/community-register/2015/20150115130395/anx_130395_en.pdf]Search in Google Scholar
[65. PAPP K, REICH K, LEONARDI CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Journal of the American Academy of Dermatology. 2015; 73(1):37-49.10.1016/j.jaad.2015.03.04926089047]Search in Google Scholar
[66. MUGHAL F, BARKER J, CAWSTON H, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the Uk. Journal of the American Academy of Dermatology. 2016; 74(5):AB243.10.1016/j.jaad.2016.02.950]Search in Google Scholar
[67. European Agency of Medicines: Biosimilars. [Accessed 22.06.2017]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp&mid=WC0b01ac0580bb8fda]Search in Google Scholar
[68. MAZUR M, OLEK-HRAB K, KARCZEWSKI J, et al. Biosimilars in dermatology. Advances in Dermatology and Allergology/Postẹpy Dermatologii i Alergologii. 2015; 32(5):384.10.5114/pdia.2014.44026469281326759547]Search in Google Scholar
[69. RADTKE MA, AUGUSTIN M. Biosimilars in psoriasis: what can we expect? JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2014; 12(4):306-12.10.1111/ddg.1229424698590]Open DOISearch in Google Scholar
[70. NAST A, ROSUMECK S, SEIDENSCHNUR K. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2015; 13(4):294-300.10.1111/ddg.1262125819235]Search in Google Scholar
[71. PUIG L. Biosimilars in psoriasis 2015: what is next? Journal of the European Academy of Dermatology and Venereology. 2016; 30(3):467-9.10.1111/jdv.1284325389042]Search in Google Scholar
[72. GRIFFITHS CE, THAÇI D, GERDES S, et al. The EGALITY study: A confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. British Journal of Dermatology. 2016.10.1111/bjd.1515227787890]Search in Google Scholar
[73. DAPAVO P, VUJIC I, FIERRO MT, et al. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 2016; 75(4):736-9.10.1016/j.jaad.2016.04.06827473452]Search in Google Scholar
[74. TICHY M, KOPOVA R, STERNBERSKY J. First experience with therapy of severe forms of psoriasis with biosimilar infliximab. Journal of the European Academy of Dermatology and Venereology. 2016; 30(3):491-3. Received November 9th, 201710.1111/jdv.1287625418715]Open DOISearch in Google Scholar